mercredi 10 juin 2020

Onco Actu du 10 juin 2020

Glioblastoma Genomes Point to Non-Coding Driver Mutations [Genome Web] 
Along with alterations affecting coding genes linked to GBM previously, the team's analyses pointed to an over-representation of non-coding mutations falling near 78 GBM-related genes.

Re­search­ers have found a mo­lecu­lar ex­plan­a­tion to a long­stand­ing en­igma in viral on­co­logy [University of Helsinki]
The oncogenic herpesvirus (HHV8 or KSHV) causes a cancer known as Kaposi’s Sarcoma. An international team of scientists led by the University of Helsinki has discovered key factors that control the genome maintenance and replication of a virus responsible for lymphatic vascular cancer.

American Cancer Society Updates Diet & Physical Activity Guideline for Cancer Prevention [ACS]
More emphasis on reducing the consumption of processed and red meat and alcohol, and increasing physical activity.

Investigators collected bone marrow samples from 214 patients at the time of diagnosis with smoldering multiple myeloma and sequenced the DNA within the tumor cells. This was a multicenter cohort encompassing multiple centers from the United States and Europe.

This novel genome-wide signature detection, coupled with proprietary mathematical inference models and machine learning techniques, provides ultra-sensitive quantification of the amount of circulating tumor DNA in the patient’s blood, accurately capturing the aggregate response of the heterogenic tumor.

Contrary to common medical guidance, chemotherapy does not appear to be the only culprit in neuropathy, a neurological side effect of cancer treatment, a new study says. Cancer itself contributes heavily, too, and the stresses on neurons appear far worse than the sum of the two causes.

In cell culture and mouse models, the researchers discovered that when they inhibited P70S6K with a drug, or genetically reduced the enzyme’s levels, they could sensitise resistant lung adenocarcinoma cells to cisplatin.

Keytruda, which brought in sales of $3.28 billion in the first quarter, has already received three U.S. regulatory approvals for different types of bladder cancers.
With repeated snafus over the last 5 months, some analysts may start to wonder if the pharma giant is leaving itself vulnerable as the competition stacks up and new combos, including TIGIT, start to take center stage.
Results will be presented at an upcoming medical meeting and will be discussed with regulatory authorities.
The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers.
The deal involves Roche technology for "universal" CAR-T cell therapies, which wouldn't require the re-engineering of a patient's own immune cells that makes Novartis' Kymriah and Gilead's Yescarta so logistically complex.

Zercepac is a biosimilar medicinal product. It is highly similar to the reference product Herceptin (trastuzumab), which was authorised in the EU on 28 August 2000.
It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement.

Sanofi's Sarclisa rejected by NICE over uncertainties on total benefit, cost-effectiveness [Fierce Pharma] 
The drug’s list price isn’t yet public. NICE's decision isn’t final and is subject to review and consultation. 

Although many will have missed out on networking opportunities and the collective excitement of witnessing the presentation of new, practice-changing data in person, the virtual format does have advantages.